Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Exclusion Criteria

• •Prior exposure to isatuximab or participated clinical studies with isatuximab.
• •Prior exposure to any agent (approved or investigational) that blocks the programmed cell death-1 (PD-1)/PD-L1 pathway.
• •Evidence of other immune related disease/conditions.
• •History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
• •Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
• •Has allogenic haemopoietic stem cell (HSC) transplant.
• •Prior treatment with idelalisib (a PI3K inhibitor).
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) \>2.
• •Poor bone marrow reserve.
• •Poor organ function.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.